Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T89950
|
|||||
| Target Name |
Calcitonin gene-related peptide (CALC)
|
|||||
| Gene Name |
NO-GeName
|
|||||
| Target Type |
Successful target
|
[1] | ||||
| Disease | [+] 1 Target-related Diseases | + | ||||
| 1 | Migraine [ICD-11: 8A80] | |||||
| UniProt ID | ||||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Approved Drug(s) | [+] 1 Approved Drugs | + | ||||
| 1 | Eptinezumab | Drug Info | Approved | Migraine | [2] | |
| Clinical Trial Drug(s) | [+] 3 Clinical Trial Drugs | + | ||||
| 1 | TEV-48125 | Drug Info | Phase 3 | Migraine | [3] | |
| 2 | ALD-403 | Drug Info | Phase 2 | Migraine | [4] | |
| 3 | PF-4427429 | Drug Info | Phase 1 | Migraine | [5] | |
| Discontinued Drug(s) | [+] 1 Discontinued Drugs | + | ||||
| 1 | CGRP | Drug Info | Discontinued in Phase 2 | Asthma | [6] | |
| Mode of Action | [+] 2 Modes of Action | + | ||||
| Inhibitor | [+] 1 Inhibitor drugs | + | ||||
| 1 | Eptinezumab | Drug Info | [2] | |||
| Modulator | [+] 3 Modulator drugs | + | ||||
| 1 | ALD-403 | Drug Info | [1] | |||
| 2 | PF-4427429 | Drug Info | [8] | |||
| 3 | CGRP | Drug Info | [9] | |||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | |||||
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 | |||||
| REF 3 | ClinicalTrials.gov (NCT03303105) Long-term Safety and Tolerability of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine. U.S. National Institutes of Health. | |||||
| REF 4 | ClinicalTrials.gov (NCT02275117) A Multicenter Assessment of ALD403 in Chronic Migraine. U.S. National Institutes of Health. | |||||
| REF 5 | ClinicalTrials.gov (NCT01117233) Study In Healthy Adult Volunteers To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04427429. U.S. National Institutes of Health. | |||||
| REF 6 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022730) | |||||
| REF 7 | TEV-48125 for the preventive treatment of chronic migraine: Efficacy at early time points. Neurology. 2016 Jul 5;87(1):41-8. | |||||
| REF 8 | Teva Announces Positive Results for TEV-48125 in Phase IIb Chronic Migraine Study Meeting Primary and Secondary Endpoints | |||||
| REF 9 | Calcitonin gene-related peptide as inflammatory mediator.Pulm Pharmacol Ther.2003;16(3):121-30. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.